ARGX 113

Drug Profile

ARGX 113

Alternative Names: ARGX113

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator arGEN-X
  • Developer argenx
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Immune thrombocytopenic purpura; Myasthenia gravis; Pemphigus vulgaris

Most Recent Events

  • 30 Oct 2017 Phase-I clinical trials in Immune thrombocytopenic purpura (In volunteers) in Netherlands (SC)
  • 30 Oct 2017 Phase-I clinical trials in Myasthenia gravis (In volunteers) in Netherlands (SC)
  • 30 Oct 2017 Phase-I clinical trials in Pemphigus vulgaris (In volunteers) in Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top